Premium
Nitric oxide donor trans‐ [RuCl([15]aneN 4 )NO] 2+ as a possible therapeutic approach for Chagas' disease
Author(s) -
Guedes Paulo MM,
Oliveira Fabiana S,
Gutierrez Fredy RS,
da Silva Grace Kelly,
Rodrigues Gerson Jhonatan,
Bendhack Lusiane Maria,
Franco Douglas W,
Do Valle Matta Maria A,
Zamboni Dario S,
da Silva Roberto Santana,
Silva João Santana
Publication year - 2010
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2009.00576.x
Subject(s) - benznidazole , chagas disease , trypanosoma cruzi , in vivo , nitric oxide , myocarditis , pharmacology , medicine , amastigote , in vitro , biology , immunology , biochemistry , parasite hosting , microbiology and biotechnology , world wide web , computer science , leishmania
Benznidazole (Bz) is the therapy currently available for clinical treatment of Chagas' disease. However, many strains of Trypanosoma cruzi parasites are naturally resistant. Nitric oxide (NO) produced by activated macrophages is crucial to the intracellular killing of parasites. Here, we investigate the in vitro and in vivo activities against T. cruzi, of the NO donor, trans-[RuCl([15]aneN(4))NO](2+).